Passionate about Research and Healthcare
Breast Cancer Awareness Month 2026
Earlier Signals, More Precise Treatment — and the Continuing Challenge of Equity
October is Breast Cancer Awareness Month, a time to raise awareness, but also to look at where the science is moving.
Breast cancer remains the most commonly diagnosed cancer among women worldwide. In 2024, an estimated 2.4 million women were diagnosed and 694,000 died from the disease. Around 70% of breast cancer deaths occur in low- and middle-income countries, where access to early diagnosis, appropriate testing and comprehensive treatment remains more limited.
The World Health Organization’s message for 2026 is simple: every story is unique, every journey matters. But behind those individual journeys, breast cancer research is undergoing an important shift.
Increasingly, the question is not simply whether cancer can be detected earlier. It is whether we can identify changes in the biology of a tumour earlier and use that information to adapt treatment before conventional signs of progression appear.
AI-supported mammography: stronger evidence emerges
Artificial intelligence is becoming increasingly visible in breast screening, but the important development is that evidence is now moving beyond retrospective studies into large randomised trials.
The MASAI trial, involving more than 105,000 women in Sweden, compared AI-supported mammography screening with standard double reading.
AI-supported screening detected 6.4 cancers per 1,000 women screened compared with 5.0 per 1,000 with standard screening. It also reduced the screen-reading workload by 44.2%, without a statistically significant increase in false-positive results.
This is encouraging evidence that AI may help radiologists identify more cancers while reducing workload.
However, increased detection is not the same as demonstrating improved long-term survival. Continued follow-up and research will be important in understanding how AI-supported screening affects interval cancers, overdiagnosis, outcomes and implementation across different populations.
Liquid biopsy: detecting resistance before the scan changes
One of the most significant recent developments comes from the use of circulating tumour DNA, or ctDNA.
Tumours can release tiny fragments of DNA into the bloodstream. Analysing these fragments through a blood test can provide information about molecular changes occurring in a cancer.
In hormone receptor-positive, HER2-negative advanced breast cancer, one important change is the development of mutations in the ESR1 gene, which can make tumours resistant to aromatase inhibitor therapy.
The Phase III SERENA-6 trial asked an unusual question: rather than waiting for a scan to show that the cancer had progressed, could doctors monitor ctDNA, identify an emerging ESR1 mutation and change treatment earlier?
Patients whose ESR1 mutation was detected while their disease remained radiologically stable were randomly assigned either to continue their existing aromatase inhibitor or switch to camizestrant, while continuing their CDK4/6 inhibitor.
Median progression-free survival was 16.0 months with camizestrant compared with 9.2 months with continued aromatase inhibitor therapy.
In September 2026, the US FDA granted camizestrant accelerated approval for this setting. It described the decision as the first FDA approval of a cancer treatment guided by detection of a resistance mutation in ctDNA before imaging showed disease progression.
That represents an important conceptual shift:
detect molecular resistance → intervene earlier → potentially delay clinical progression.
There is an important caveat. The FDA has required further evidence to confirm whether intervening at this earlier molecular stage translates into meaningful longer-term clinical benefit.
Treatment is becoming increasingly molecular
The wider direction of breast cancer treatment is also becoming clearer.
Rather than treating breast cancer as a single disease, therapy increasingly depends on its molecular characteristics — including hormone-receptor status, HER2 status and specific genetic alterations.
In 2026, additional treatments targeting ESR1-mutated breast cancer have received regulatory approvals. These include the targeted protein degrader vepdegestrant, while the FDA has also approved imlunestrant combined with abemaciclib for certain patients with ESR1-mutated advanced or metastatic disease.
These developments reinforce a broader movement towards biomarker-led and increasingly adaptive cancer treatment.
The innovation gap
Scientific progress is important. Access to it is equally important.
AI-supported mammography requires appropriate imaging infrastructure, validated technology and trained clinical teams.
ctDNA-guided treatment depends on access to molecular testing, laboratory capacity, appropriate medicines and health systems capable of acting on the results.
And increasingly personalised treatment is of limited value to populations who face delayed diagnosis or cannot access standard therapy in the first place.
WHO’s Global Breast Cancer Initiative is therefore focused on three practical targets: increasing the proportion of breast cancers diagnosed at stages I and II, reducing delays between presentation and diagnosis, and ensuring more people complete recommended treatment.
Our Perspective
At Azurite Health, we see awareness as a starting point, not an endpoint.
The science of breast cancer is becoming more precise. AI may support earlier detection. Blood-based biomarkers may allow clinicians to see molecular resistance before progression becomes visible on a scan. New treatments are increasingly matched to the biology of an individual cancer.
But innovation only matters if people can reach it.
That requires representative clinical research, strong local research and diagnostic infrastructure, timely access to testing and treatment, and health systems capable of translating scientific advances into everyday care.
The next challenge is not simply developing better innovation. It is making sure that innovation reaches everyone.
World Health Organization — Breast Cancer Awareness Month 2026 and current breast cancer fact sheet. WHO: Breast Cancer Awareness Month 2026
The Lancet Digital Health / PubMed — MASAI randomised controlled trial of AI-supported mammography. MASAI trial on PubMed
New England Journal of Medicine — First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. SERENA-6 trial in NEJM
US Food and Drug Administration — September 2026 accelerated approval of camizestrant. FDA camizestrant approval
Azurite Health: Engaging at Key Healthcare Conferences in 2026
We will be participating in selected conferences and forums throughout 2026, engaging with partners on health systems, research readiness, and sustainable innovation.
If you would like to connect with our team, please contact us at info@azurite-health.co.uk.
.
Protecting Our Community: Join Azurite Health in Supporting the NHS - Vaccination Programmes
Azurite Health is committed to promoting community health by supporting vital public health initiatives like the NHS Flu and Shingles Vaccination Programmes. It's important to remember that these vaccines are crucial for preventing severe illness and safeguarding our community’s well-being.
Flu, in particular, can spread quickly and lead to serious complications, especially among older adults, young children, and those with pre-existing conditions. The NHS offers free flu vaccines to those at higher risk, including people aged 65 and over, pregnant women, and individuals with long-term health conditions. By getting your flu vaccine, you not only protect yourself but also help reduce the strain on the NHS.
At the same time, we also continue to support the NHS Shingles Vaccination Programme. Shingles can cause severe pain and long-term complications, especially in older adults. The NHS offers a free shingles vaccine to those aged 70 to 79 to help prevent this condition. Getting vaccinated not only protects you from shingles but also helps keep our community healthy and strong.
We encourage everyone who qualifies to take advantage of these vaccination opportunities. Together, we can protect ourselves and our community from flu and shingles this season.
For more information on eligibility and vaccination sites, please visit the official NHS website:
Let’s work together for a healthier future by supporting the NHS vaccination programmes.
Azurite Health Values
Innovation. Equality. Science.
Our daily work is inspired by our values.
Science: Our foundation lies in rigorous scientific principles, guiding every decision and action.
Passion: Our heart beats for healthcare, research, and exceptional patient care.
Innovation: We're at the forefront, harnessing advanced technologies and novel solutions to transform patient and caregiver experiences.
Integrity: A just, equitable, and supportive workspace is our commitment—where every voice matters.
Sustainability: Beyond our work, we're stewards for the environment, pledging to uphold sustainable practices.
Community: We're more than a company; we're a collective, sharing and enriching healthcare knowledge every step of the way.
